Mineralys: 2nd Half 2024 Hypertension Data Readout [Seeking Alpha]
Mineralys Therapeutics, Inc. (MLYS)
Company Research
Source: Seeking Alpha
Results from the phase 3 ADVANCE-HTN study using lorundrostat for the treatment of patients with uncontrolled or resistant hypertension, expected in the 2nd half of 2024. Mineralys is also conducting a phase 2 study for the use of lorundrostat in treating hypertension in Chronic Kidney Disease patients, with results expected in the first half of 2024 or Q1 2025. The global hypertension market is expected to reach $43.18 billion by 2030. Looking for more investing ideas like this one? Get them exclusively at Biotech Analysis Central. Learn More » Mineralys Therapeutics, Inc. NASDAQ: MLYS ) has made significant progress for its pipeline, because it has been able to launch two phase 3 studies, which are using lorundrostat for the treatment of patients with uncontrolled and resistant hypertension. One of these two late-stage studies, known as ADVANCE-HTN, is expected to have a data readout in the 2nd half of 2024. However, the second late-stage study for this particular program i
Show less
Read more
Impact Snapshot
Event Time:
MLYS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MLYS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MLYS alerts
High impacting Mineralys Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
MLYS
News
- Mineralys Therapeutics to Announce First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 9, 2024GlobeNewswire
- Mineralys Therapeutics, Inc. (NASDAQ: MLYS) is now covered by analysts at The Goldman Sachs Group, Inc.. They set a "buy" rating and a $30.00 price target on the stock.MarketBeat
- Mineralys Therapeutics, Inc. (NASDAQ: MLYS) had its "outperform" rating re-affirmed by analysts at Lifesci Capital.MarketBeat
- Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Q4 2023 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Mineralys Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update [Yahoo! Finance]Yahoo! Finance
MLYS
Earnings
- 3/21/24 - Beat
MLYS
Sec Filings
- 4/15/24 - Form 4
- 4/12/24 - Form EFFECT
- 4/11/24 - Form 424B5
- MLYS's page on the SEC website